Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atezolizumab - Genentech

Next Previous
X
Search
Drug Profile

Atezolizumab - Genentech

Alternative Names: Anti-PDL-1-Genentech/Roche; MPDL-3280A; RG-7446; RG7446-42; RO-5541267; TECENTRIQ; Tecentriq Hybreza; Tecentriq SC

Latest Information Update: 20 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; University Medical Center Groningen
  • Developer Amgen; ARCAGY/GINECO Group; Austrian Breast & Colorectal Cancer Study Group; AVEO Oncology; Basilea Pharmaceutica; BioLineRx; Chugai Pharmaceutical; Clovis Oncology; Dana-Farber Cancer Institute; Duke University; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; Exelixis; Fondazione Michelangelo; Galecto Inc; Genentech; GERCOR; German Breast Group; Gradalis; H. Lee Moffitt Cancer Center and Research Institute; Immune Design; Incyte Corporation; Johns Hopkins University; Kaiser Permanente; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Center (Korea); National Cancer Institute (USA); Netherlands Cancer Institute; NSABP Foundation; Nykode Therapeutics; Oncolytics Biotech; Roche; Roche Pharma AG; Sanofi; University Hospital Southampton NHS Foundation Trust; University Medical Center Groningen; University of California; University of California at San Francisco; University of Florida; University of Oklahoma; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer; Soft tissue sarcoma; Malignant melanoma; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; Urogenital cancer
  • Preregistration Solid tumours
  • Phase III Bladder cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Malignant-mesothelioma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma
  • Phase II Adrenocortical carcinoma; Anal cancer; Biliary cancer; Brain metastases; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Endometrial cancer; Gastric cancer; Gynaecological cancer; Head and neck cancer; HER2 positive breast cancer; Malignant thymoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Penile cancer; Phaeochromocytoma; Rectal cancer; Soft tissue sarcoma; Squamous cell cancer; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Acute myeloid leukaemia; Cholangiocarcinoma; Follicular lymphoma; Gallbladder cancer; Glioblastoma; Hodgkin's disease; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Pancreatic cancer
  • No development reported Haematological malignancies; Multiple myeloma
  • Discontinued Myelodysplastic syndromes

Most Recent Events

  • 20 Sep 2024 Registered for Breast cancer (Combination therapy, First-line therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease) in USA (SC)
  • 12 Sep 2024 Registered for Liver cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (SC)
  • 12 Sep 2024 Registered for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Adjuvant therapy) in USA (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top